Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: Limited sampling strategies

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 434-438

  Sibbald, Cathryn ^a   Seto, Winnie ^a   Taylor, Tracey ^a   Saunders, E Fred ^a   Doyle, John ^b   Dupuis, L Lee ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cyclosporine; Hematopoietic stemcell transplant; Pediatrics; Pharmacokinetics

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; BLOOD; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; PRESCHOOL CHILD; REGRESSION ANALYSIS;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA; MALE; REGRESSION ANALYSIS;

EID: 58149130304     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318180c662     Document Type: Article

References (20)

1. Ruutu T, Niederwieser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997;19: 759-764.
2. Peters C, Minkov M, Gadner H, et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000;26:405-411.
3. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation. 2002; 73:S12-S18.
4. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C2 monitoring: a review. Transplantation. 2002;73:S3-S11.
5. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
6. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68:55-62.
7. Trompeter R, Fitzpatrick M, Hutchinson C, et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (NeoralTM) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 2003;7:282-288.
8. Yee GC, Self SG, McGuire TR, et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988;319:65-70.
9. Martin P, Bleyzac N, Souillet G, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003;32:777-784.
10. Ghalie R, Fitzsimmons WE, Weinstein A, et al. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother. 1994;28:379-383.
11. Punnett A, Sung L, Price V, et al. Achievement of target cyclosporine concentrations as a predictor of severe acute GvHD in children receiving cyclosporine and methotrexate prophylaxis. Ther Drug Monit. 2007;29: 750-757.
12. Cole M, Boddy AV, Kearns P, et al. Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: how much do we really know? Pediatr Blood Cancer. 2006;46:723-727.
13. Dupuis LL, Taylor T, Saunders EF. Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. Pharmacotherapy. 2006;26:15-22.
14. Giesbrecht E, Soldin S, Wong P. A reliable high-performance liquid chromatographic micromethod for the measurement of cyclosporine in whole blood. Ther Drug Monit. 1989;11:332-336.
15. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
16. Ting LS, Partovi N, Levy RD, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy. 2006;26: 1232-1240.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
18. Bland JM, Altman DG. Comparing methods of measurement: why plotting differences against standard method is misleading. Lancet. 1995; 346:1085-1087.
19. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-218.
20. Papadopoulou A, Lloyd DR, Williams MD, et al. Gastrointestinal and nutritional sequelae of bone marrow transplantation. Arch Dis Child. 1996;75:208-213.